Travere Therapeutics, Inc. TVTX Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s accounts payable?
- Travere Therapeutics, Inc. (TVTX) reported accounts payable of $12.91M in Q1 2026.
- How has Travere Therapeutics, Inc.'s accounts payable changed year-over-year?
- Travere Therapeutics, Inc.'s accounts payable decreased by 16.0% year-over-year, from $15.37M to $12.91M.
- What is the long-term trend for Travere Therapeutics, Inc.'s accounts payable?
- Over 5 years (2020 to 2025), Travere Therapeutics, Inc.'s accounts payable has grown at a 15.4% compound annual growth rate (CAGR), from $12.13M to $24.8M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.